Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
naltrexone extended-release
- Development stage
- Approved
- Lead developer
- Alkermes
- Modality
- Small Molecules
- Administration
- Intramuscular, Oral
01
Overview
Naltrexone extended-release is a microsphere formulation of the opioid antagonist medication naltrexone, administered by intramuscular (IM) gluteal injection once a month. It works by binding to and blocking opioid receptors in the brain, which reduces opioid cravings and prevents the euphoric and sedative effects of opioids. The extended-release injectable form helps address patient noncompliance, which can limit the effectiveness of oral naltrexone. Unlike oral naltrexone which has a sawtooth pattern of peaks and troughs with each daily dose, the extended-release formulation provides a more consistent delivery of the medication over time.
- Brand names
- Vivitrol
- Other names
- XR-NTXXR-naltrexone
02
Targets
DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on naltrexone extended-release.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on naltrexone extended-release.